



# **COVID-19 Variant Surveillance Report**

Week ending July 10, 2021 (MMWR week 27)


## **Variant Surveillance- Cumulative Summary**

Lineage (WHO Classification)	Proportion of Variant Sequenced	Proportion of Variant		
	from Dec 20, 2020 (%)	Sequenced in last 4 weeks (%)		
Variant of Concern				
<b>B.1.1.7</b> (Alpha)	38.6%	10.3%		
<b>B.1.617.2</b> (Delta) <sup>§</sup>	4.5%	74.5%		
<b>P.1</b> (Gamma)	2.3%	3.7%		
<b>B.1.351</b> (Beta)	0.1%	0.2%		
Variant of Interest				
<b>B.1.526</b> (lota)	24.0%	1.7%		
B.1.526.1	3.3%	0.0%		
<b>B.1.427, B.1.429</b> (Epsilon)*	1.3%	0.2%		
<b>B.1.525</b> (Eta)	0.2%	0.0%		
<b>P.2</b> (Zeta)	0.1%	0.0%		
B.1.617	0.1%	0.0%		
<b>B.1.617.1</b> (Kappa)	0.1%	0.0%		
Other Lineages	25.4%	9.5%		
Total Number of Specimens Sequenced**	14464	651		

<sup>§</sup> Includes AY.3 variant. CDC announced July 6, 2021 that SARS-CoV-2 variants AY.1, AY.2 and AY.3 are now aggregated with Delta variant B.1.617.

For CDC definitions of variant of concern and variant of interest visit: https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html#Concern

## **COVID-19 Variant Surveillance by Specimen Collected Week- Cumulative Summary**




Percentages represent the proportion found in the specified variant lineage. "Other" represents 158 additional lineages which include other COVID-19 variants not classified as variants of concern or variants of interest.

<sup>\*</sup> Deescalated from a Variant of Concern on June 29, 2021, due to the significant decrease in the proportion of B.1.429 lineage viruses circulating nationally and available data.

<sup>\*\*</sup> Includes all sequencing results reported by Commercial Labs (LabCorp, Aegis Sciences Corporation, Infinity Biologix and Quest Diagnostics) and the State Public Health Lab that have been submitted for surveillance purposes.

<sup>\*</sup>Specimens collected 7/4/2021 – 7/10/2021 reflects data for one week with a total of 182 specimens.

## COVID-19 Variant Surveillance by State Region- Previous 4 weeks Summary\*



#### **Variant Details**

Name (Pango Lineage)	First Detected	CDC Variant Classification	WHO Label
B.1.1.7	United Kingdom	Variant of Concern	Alpha
B.1.351	South Africa	Variant of Concern	Beta
B.1.617.2	India	Variant of Concern	Delta
P.1	Brazil	Variant of Concern	Gamma
B.1.427,	USA-California	Variant of Interest	Epsilon
B.1.429	USA-CalliUlTila	variant of interest	грэнон
B.1.525	USA-New York	Variant of Interest	Eta
B.1.526	USA-New York	Variant of Interest	lota
B.1.526.1	USA-New York	Variant of Interest	
P.2	Brazil	Variant of Interest	Zeta
B.1.617	India	Variant of Interest	
B.1.617.1	India	Variant of Interest	Карра

\*Each regional chart represents the proportion of the specified variant lineage and is based on sequencing results from the 4 weeks prior to the week of July 10, 2021. There is an approximately 16-24-day time lag between specimen collection and report of sequencing results to NJDOH. "Other" represents additional lineages which include other COVID-19 variants not classified as variants of concern or variants of interest.

Includes all sequencing results reported by Commercial Labs (LabCorp, Aegis Sciences Corporation, Infinity Biologix and Quest Diagnostics) and the State Public Health Lab that have been submitted for surveillance purposes.

Data reported is based on a subset of sampled specimens from NJ residents sequenced for COVID-19 variant surveillance.